Rethinking Depression As A Network Disorder
As advances in interventional psychiatry continue to reshape how clinicians understand severe mood disorders, depression is increasingly viewed as a disorder of dysfunctional brain networks rather than isolated brain regions. This shift has fueled interest in deep brain stimulation, or DBS, as a potential intervention for patients who do not respond to medication, psychotherapy, or noninvasive neuromodulation. A recent scoping review published in Biological Psychiatry Global Open Science offers a timely synthesis of what DBS has achieved so far and what remains unresolved by examining the current state of interventional psychiatry research in treatment-resistant depression.
Why Existing Treatments Still Fall Short
Treatment-resistant depression remains one of the most challenging problems in psychiatry. Even with modern antidepressants, ketamine-based therapies, and transcranial magnetic stimulation, a significant subset of patients experience persistent symptoms, impaired functioning, and elevated suicide risk. DBS emerged from this therapeutic gap, offering the possibility of directly modulating dysfunctional circuits implicated in mood regulation. However, despite two decades of investigation, DBS has not yet achieved widespread clinical adoption for depression.
Introducing Deep Brain Stimulation For Treatment-Resistant Depression
Deep brain stimulation for treatment-resistant depression involves surgically implanting electrodes into specific brain regions and delivering continuous electrical stimulation. Unlike lesion-based psychosurgery of the past, DBS is adjustable and theoretically reversible. The underlying goal is to normalize pathological network activity across limbic, cognitive, and reward circuits implicated in depression.
Why Study Design And Conceptual Models Matter
The new scoping review analyzed peer-reviewed DBS studies using PRISMA 2020 guidelines and highlighted a central issue: depression itself is inconsistently defined across trials. Some studies emphasize mood severity, others target anhedonia, anxiety, or psychomotor slowing. Without a shared conceptual framework linking symptoms to neural circuits, selecting stimulation targets becomes inconsistent and outcomes difficult to compare.
Key Findings From The Scoping Review
Across 48 studies, DBS targets varied widely, including the subcallosal cingulate, nucleus accumbens, ventral capsule, and medial forebrain bundle. Most trials reported some degree of symptom improvement, but response rates and durability varied substantially. Notably, nearly 17 percent of studies failed to specify which symptom dimensions were expected to respond to stimulation. This lack of clarity limits interpretability and complicates replication.
Interpreting Mixed Clinical Results
The review does not conclude that DBS is ineffective. Instead, it suggests that current evidence is fragmented. Symptom rating scales such as the Montgomery-Åsberg Depression Rating Scale dominate outcome assessment, while functional recovery, quality of life, and patient-reported outcomes are less consistently measured. As a result, clinically meaningful improvements may be underestimated or poorly characterized.
Mechanisms And Circuit-Level Insights
From a mechanistic standpoint, DBS is thought to induce activity-dependent reprogramming of focal circuits that propagate across broader brain networks. Rather than simply inhibiting or exciting a single region, stimulation may alter pathological patterns of connectivity, emotional salience processing, and cognitive control. These effects align with network-based models of depression that emphasize limbic-cortical dysregulation.
What Makes This Review Different
Unlike earlier narrative reviews, this scoping review systematically maps stimulation targets to conceptual models of depression. It underscores that anatomical heterogeneity is not inherently problematic if it reflects deliberate targeting of distinct symptom profiles. The problem arises when target selection is disconnected from explicit hypotheses about symptom-circuit relationships.
Clinical Implications For The Field
For clinicians and researchers, the message is clear. Deep brain stimulation for treatment-resistant depression may require a precision psychiatry framework to succeed. This includes standardized definitions of treatment resistance, clearer symptom mapping, incorporation of neuroimaging and electrophysiology, and greater emphasis on functional outcomes. The review also calls for exploration of unilateral and multitarget approaches, which may better reflect the distributed nature of depressive pathology.
A Measured Look Toward The Future
DBS remains one of the most ambitious interventions in psychiatry. While its promise is supported by compelling neurobiological rationale, its clinical benefits are not yet fully established. This review suggests that progress will depend less on technological advances alone and more on aligning clinical models, targets, and outcomes within a coherent network-based framework.
Citations
Puke L, Rosselet Amoussou J, von Gunten A, Elowe J. Has deep brain stimulation shown its full potential in treatment-resistant depression A scoping review. Biological Psychiatry Global Open Science. 2025. https://doi.org/10.1016/j.bpsgos.2025.100682
Mayberg HS. Limbic-cortical dysregulation A proposed model of depression. Journal of Neuropsychiatry and Clinical Neurosciences. 1997;9(3):471–481. https://pubmed.ncbi.nlm.nih.gov/9276848/